PHAXIAM Therapeutics S.A. - Asset Resilience Ratio

Latest as of June 2024: 3.74%

PHAXIAM Therapeutics S.A. (PHXM) has an Asset Resilience Ratio of 3.74% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€1.46 Million

≈ $1.71 Million USD Cash + Short-term Investments

Total Assets

€39.11 Million

≈ $45.72 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2023)

This chart shows how PHAXIAM Therapeutics S.A.'s Asset Resilience Ratio has changed over time. Check PHAXIAM Therapeutics S.A. (PHXM) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down PHAXIAM Therapeutics S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of PHAXIAM Therapeutics S.A..

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€1.46 Million	3.74%
Short-term Investments	€0.00	0%
Total Liquid Assets	€1.46 Million	3.74%

Asset Resilience Insights

Limited Liquidity: PHAXIAM Therapeutics S.A. maintains only 3.74% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

PHAXIAM Therapeutics S.A. Industry Peers by Asset Resilience Ratio

Compare PHAXIAM Therapeutics S.A.'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Samsung Biologics Co Ltd KO:207940	Biotechnology	5.66%
Revolution Medicines Inc NASDAQ:RVMD	Biotechnology	65.10%
Abivax SA PA:ABVX	Biotechnology	2.34%
Asymchem Laboratories Tian Jin Co Ltd SHE:002821	Biotechnology	5.07%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	43.36%
SOLENO THERAPEUT. DL-001 F:6XC	Biotechnology	41.74%
REMEGEN CO. LTD YC 1 F:REG	Biotechnology	16.77%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

Annual Asset Resilience Ratio for PHAXIAM Therapeutics S.A. (2016–2023)

The table below shows the annual Asset Resilience Ratio data for PHAXIAM Therapeutics S.A..

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-12-31	20.41%	€10.47 Million ≈ $12.25 Million	€51.31 Million ≈ $59.98 Million	-64.35pp
2022-12-31	84.77%	€38.83 Million ≈ $45.40 Million	€45.81 Million ≈ $53.56 Million	+33.58pp
2021-12-31	51.19%	€34.18 Million ≈ $39.96 Million	€66.77 Million ≈ $78.06 Million	-4.10pp
2020-12-31	55.29%	€44.45 Million ≈ $51.97 Million	€80.40 Million ≈ $94.00 Million	-6.45pp
2019-12-31	61.74%	€73.19 Million ≈ $85.56 Million	€118.55 Million ≈ $138.59 Million	-18.32pp
2018-12-31	80.06%	€134.37 Million ≈ $157.09 Million	€167.84 Million ≈ $196.22 Million	-3.66pp
2016-12-31	83.72%	€37.65 Million ≈ $44.01 Million	€44.97 Million ≈ $52.57 Million	--

pp = percentage points

About PHAXIAM Therapeutics S.A.

PA:PHXM France Biotechnology

Market Cap

$1.18 Million

€1.01 Million EUR

Market Cap Rank

#30574 Global

#571 in France

Share Price

€0.10

Change (1 day)

+0.00%

52-Week Range

€0.10 - €0.10

All Time High

€283.83